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Summary
PTEN, a protein tyrosine phosphatase with homology
to tensin, is a tumor-suppressor gene on chromosome
10q23. Somatic mutations in PTEN occur in multiple
tumors, most markedly glioblastomas. Germ-line mu-
tations in PTEN are responsible for Cowden disease
(CD), a rare autosomal dominant multiple-hamartoma
syndrome. PTEN was sequenced from constitutional
DNA from 25 families. Germ-line PTENmutationswere
detected in all of five families with both breast cancer
and CD, in one family with juvenile polyposis syndrome,
and in one of four families with breast and thyroid tu-
mors. In this last case, signs of CD were subtle and were
diagnosed only in the context of mutation analysis.
PTENmutations were not detected in 13 families at high
risk of breast and/or ovarian cancer. No PTEN-coding-
sequence polymorphisms were detected in 70 independ-
ent chromosomes. Seven PTEN germ-line mutations oc-
curred, five nonsense and two missense mutations, in six
of nine PTEN exons. The wild-type PTEN allele was
lost from renal, uterine, breast, and thyroid tumors from
a single patient. Loss of PTEN expression was an early
event, reflected in loss of the wild-type allele in DNA
from normal tissue adjacent to the breast and thyroid
tumors. In RNA from normal tissues from three families,
mutant transcripts appeared unstable. Germ-line PTEN
mutations predispose to breast cancer in association
with CD, although the signs of CD may be subtle.
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Introduction
The protein tyrosine phosphatase and tensin homologue
PTEN is a tumor suppressor of glioblastoma, breast can-
cer and prostatic cancer (Li and Sun 1997; Li et al. 1997;
Steck et al. 1997), and malignant melanoma (Guldberg
et al. 1997). The gene has at least three names: “PTEN”
(phosphatase with tensin homology; Genbank accession
number U93051), “MMAC1” (mutated in multi-
ple advanced cancers; Genbank accession number
U92436), and “TEP1” (TGFB-regulated and epithelial-
cell–enriched phosphatase; Genbank accession number
U96180). In primary breast carcinomas, both somatic
and germ-line PTEN mutations occur, albeit at low fre-
quency (Rhei et al. 1997). Previous observations of loss
of heterozygosity (LOH) at chromosome 10q23 in fol-
licular thyroid cancer and endometrial cancers suggested
that PTEN might act as a tumor suppressor for these
cancers as well (Jones et al. 1994; Zedenius et al. 1995).
In patients with Cowden disease (CD; MIM 158350
[Hanssen and Fryns 1995]), germ-line mutations in
PTEN have been identified (Liaw et al. 1997; Nelen et
al. 1997). Germ-line PTEN mutations are also associated
with the closely related Bannayan-Zonana syndrome
(Marsh et al. 1997).
In this report, we evaluate families with inherited pre-
disposition to breast cancer and/or CD or related syn-
dromes, for germ-line mutations in PTEN. We identify
and characterize germ-line point mutations in PTEN in
seven families, describe the cancer and other phenotypes
associated with each of these mutations, and demon-
strate somatic loss of the wild-type PTEN allele in the
associated tumors.
Subjects and Methods
Family Ascertainment
Twenty-five families were included in this analysis.
Five families (families 97, 903, 1085, 1130, and 1163;
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Table 1
Phenotypes Associated with Inherited Mutations in PTEN
MUTATION(S) EFFECT FAMILY
PATIENT
(SEX)
PHENOTYPE (AGE [IN YEARS] AT DIAGNOSIS)
Skin
Lesions Breast Endometrium Thyroid CNS
Gastrointestinal
Tract
68 TrA L22X F903 I-2 (F)  Ca (46)
F903 II-1 (F)  Ca (24) Fol Ca (18) L Hem
328 CrT Q109X 1130 I-2 (F)  Ca (34)
565 ArT R188X F1085 I-2 (F)  Bil Ca (31) Fol Ad Nf G, D, C polyps
F1085 II-1 (F)  Ad (29)
F1085 II-2 (F)  C polyps
697 CrT R232X 97 II-1 (F)  Ca (27) C polyps
1003 CrT R334X F241 I-1 (M)  Macro Sm Int Ca (34)
F241 II-2 (M)  Macro C, Sm Int polyps
1003 CrT R334X 227 II-1 (F)  DCIS (41) Ca (42) Fol Ad (42) Macro R Ca (42)
1028 TrA V332E F1163 I-2 (F) Ca (50) Ad (49) Neu (33, 34)
and and F1163 II-2 (F)  Ad (30) Ca (48) Fol Ad (32, 40) G, C polyps (37, 38)
1039 TrC F346L F1163 II-3 (F) Atyp H (33) Ca (42) Fol Ad (33) D polyps (31)
F1163 II-4 (M) Pin (42) C polyps
F1163 II-5 (F) Ca (42)
F1163 III-1 (F) Ad (17) Pap Ca (11)
NOTE.—Ad  adenoma; Atyp H  atypical hyperplasia; Bil  bilateral; C  colon; Ca  adenocarcinoma; D  duodenal; DCIS  ductal
carcinoma in situ; Fol  follicular; G  gastric; Hem  hemangioma; L  liver; Macro  macrocephaly; Neu  malignant neuroma; Nf 
neurofibroma; Pap  papillary; Pin  pineal-gland tumor; R  renal cell; and Sm Int  small intestine. A plus sign () denotes a chronic
condition.
table 1) were ascertained for co-occurrence of breast
cancer and CD in the same family. Four other families
(including family 227; table 1) were ascertained for co-
occurrence of breast and thyroid tumors without definite
diagnosis of CD, although the proband of family 227
was subsequently evaluated as having features of the
syndrome (table 1). Thirteen families at high risk of
breast, ovarian, and/or prostate cancer but with no de-
tected signs of CD were also included. At least one af-
fected member in each of these 13 families had wild-
type sequences at BRCA1 and BRCA2; in 2 families,
linkage of cancer predisposition to markers flanking
PTEN yielded small positive LOD scores (1.3 and 1.2).
Three other families with diagnoses of CD were in-
cluded. Family 241 (table 1) was diagnosed with both
juvenile polyposis syndrome (MIM 174900) and CD. In
another CD family, individuals had macrocephaly, skin
lesions, and mental retardation but no cancer, in three
generations. In a third CD family, affected individuals
had thyroid adenomas, intestinal polyps, neurofibromas,
lipomas, and colon cancer, at ages 48 and 68 years.
Of the families described above, seven (including 903,
1085, 1130, and 1163) were evaluated clinically at the
Norwegian Radium Hospital. Three families (including
227 and 241) were evaluated clinically at the University
of Washington hospitals. The other families were from
our series of families at high risk of breast and ovarian
cancer. Protocols for human subjects were approved by
the institutional review boards at the University of Wash-
ington, the Norwegian Radium Hospital, and other col-
laborating institutions, as appropriate.
Lymphoblast cell lines were prepared (Henle and
Henle 1970; Raskind et al. 1984), and DNA was ex-
tracted from cell lines and from whole blood, by use of
a high–salt-extraction method (Gentra Systems).
Genotyping Families and Tumors
Markers D10S583, D10S215, D10S541, D10S573,
and D10S564 were used to determine haplotypes for
pedigree analysis and for evaluation of LOH in tumors.
Primer sequences for these markers are available on-line
from the GenBank (http://www.ncbi.nlm.nih.gov/gen-
bank/queryform.html). Markers were typed by use of
PCR conditions and electrophoresis protocols described
in the work of Friedman et al. (1994).
Dissection of Tumor Blocks
Paraffin-embedded tissue samples were cut into 5-mi-
cron sections for staining with hematoxalin and eosin.
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Table 2
Primers That Amplify PTEN cDNA
EXONS
PRIMER
ALIGNMENT
TO PUBLISHED
CDNA SEQUENCES
(nt)
SIZE
(nt)Forward Reverse
U93051
(PTEN)
U92436
(MMAC)
1–5 5′-CCCAGACATGACAGCCATCATC-3′ 5′-GTGGTGGGTTATGGTCTTCAAAAG-3′ 1–289 1028–1323 296
4–6 5′-CTGAAAGACATTATGACACCGCC-3′ 5′-GTCTCTGGTCCTTACTTCCCCATAG-3′ 215–486 1249–1520 272
5–7 5′-GGAAAGGGACGAACTGGTGTAATG-3′ 5′-AGCTGGCAGACCACAAACTGAG-3′ 379–659 1413–1693 281
6 and 7 5′-CAATGTTCAGTGGCCGAACTTG-3′ 5′-TTTTCTGAGGTTTCCTCTGGTCC-3′ 611–866 1645–1900 256
7–9 5′-CAAAGTAGAGTTCTTCCACAAACAG-3′ 5′-TAGCCTCTGGATTTGACGG-3′ 759–1078 1763–2112 320
With the H- and E-stained slide as a guide, normal and
tumor cells were microdissected from adjacent 10-mi-
cron sections that had also been deparaffinized. Ge-
nomic DNA was extracted from the microdissected cells
by use of the manufacturer’s suggested protocol (Gentra
Systems).
Sequencing Genomic DNA, for PTEN Mutations
To analyze patient DNA for mutations in the PTEN
gene, nested PCR products corresponding to each of the
nine exons were amplified. PCR primers are as described
by Steck et al. (1997). PCR products were purified by
centrifugation through Sephacryl 300 (Sigma) in 96-well
plates (Nalge Nunc International). Purified PCR prod-
ucts were quantified by visual inspection following elec-
trophoresis through 2% agarose gels and ethidium bro-
mide staining. Patient samples were sequenced by use of
Energy Transfer Dye Primers (Amersham). The sequenc-
ing products were resolved on an ABI377 fluorescent
DNA sequencer. Base calling of the trace files was done
by use of the ABI sequence-analysis software version 3.0.
PTEN-coding sequence and flanking splice junctions
were sequenced from 70 independent normal
chromosomes.
Transcript Analysis
Isolation of poly(A) RNA was performed by use of
oligo-dT cellulose in a high-salt environment (Sambrook
et al. 1989). Patient and control mRNA was reverse
transcribed with random hexamers (Amersham) and Su-
perscript Moloney murine leukemia virus RTase (Gibco-
BRL), by use of standard procedures. Table 2 indicates
the primer pairs used to amplify cDNA, the exons am-
plified by each pair, and the sizes of amplified products.
PCR was performed for 35 cycles, at 94C for 15 s,
55C for 15 s, and 72C for 1 min, and the products
were purified by centrifugation through Sephacryl-300
columns (Sigma). Purified PCR products were cycle se-
quenced by use of dye-terminator chemistry (Perkin El-
mer–ABI). Sequencing products were resolved on 4%
LongRanger acrylamide gels (FMC), with an ABI-377
fluorescent sequencer.
The existence of a pseudogene similar to PTEN com-
plicates mutation analysis of PTEN cDNA. We used
cDNA to evaluate stability of mutant PTEN transcripts
but not as the template for original mutation detection.
Variants detected in cDNA can be inferred to be from
the PTEN gene if they are also observed in genomic DNA
amplified with PTEN-specific genomic primers.
Results
Mutations in Families
Mutations in the PTEN-coding sequence were iden-
tified in the seven families illustrated in figure 1. All seven
mutations involved single-nucleotide substitutions. Six
were nonsense mutations leading to immediate stops in
exons 1 and 5–8. One variant comprised two missense
mutations in exon 9, 1028 TrA (V342I) and 1039 TrC
(F346L), on the same parental chromosome. No poly-
morphisms in the PTEN-coding sequence were detected
in any of 70 unrelated chromosomes.
Germ-line mutations in PTEN and their associated
phenotypes are indicated in table 1 and figure 1. Multiple
invasive cancers occurred in the seven families with
germ-line mutations. Among 10 women 130 years of
age who had confirmed or probable germ-line muta-
tions, there have been eight breast cancers, three en-
dometrial cancers, one thyroid cancer, one malignant
neuroma, and one renal-cell carcinoma. Of the two adult
men with germ-line mutations, one died of intestinal
cancer at age 35 years, and the other was diagnosed
with brain cancer at age 42 years.
Nonsense mutation 697 CrT in individual 9701 is de
novo. Parentage in family 97 was verified by multiple
markers on chromosome 10 (fig. 1). Both parents have
wild-type sequence at bp 697 (fig. 2). It is not clear in
which parental chromosome the new mutation occurred.
Nonsense mutation R232X was observed previously in
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Figure 1 Cancers and noninvasive lesions in families with PTEN germ-line mutations. Symbols are divided into segments on the basis of
organ site, with blackened quadrants representing cancers and with gray-shaded quadrants representing noninvasive tumors. PTEN mutations
are indicated above each family, and the heterozygous variant (VN) or homozygous normal (NN) genotype for each tested individual is shown
below the symbol representing that individual. Haplotypes comprising five markers flanking PTEN are shown for families 227 and 241, to
demonstrate the independence of the 1003 CrT mutation. PTEN genotypes and marker haplotypes for family 97 indicate that the PTEN
mutation in the daughter is de novo.
a CD patient (Liaw et al. 1997) and occurs in a potential
tyrosine phosphate–acceptor motif (Steck et al. 1997).
The paired missense mutations in family 1163 oc-
curred in both affected relatives for whom DNA was
available. The wild-type transcript was present, but the
mutant transcript was absent, in RNA prepared from
whole blood of the affected individuals (fig. 2). Hence
the two missense mutations are likely to be on the same
chromosome. Mutation 1028 TrA changes the exon 9
splice acceptor from tagGT to tagGA and so may lead
to aberrant splicing of this last exon. The instability
could be due to the missense mutations or to aberrant
splicing.
Nonsense mutation 1003 CrT appeared in both in-
dividual 22701 and family 241, as independent muta-
tions. The haplotype constructed from D10S573,
D10S215, D10S541, D10S564, and D10S583 in family
241 (fig. 1) shares no alleles with the comparable hap-
lotype in patient 22701. Data from LOH studies of tu-
mor specimens further suggests that allele 7 at D10S541
is on the haplotype with the mutation in patient 22701
(see below).
No germ-line mutations in the PTEN-coding sequence
were detected in two families with CD but no early-
onset cancers. Nor were germ-line PTEN mutations de-
tected in any of the 13 breast cancer families that have
wild-type sequence at BRCA1 and BRCA2. With the
screening method that we employed, genomic deletions
of an exon or more would not have been detected. How-
ever, large deletions do not appear to account for a sub-
stantial proportion of germ-line PTEN mutations, al-
though these are common as somatic alterations (Li et
al. 1997; Steck et al. 1997).
LOH in Tumors
Biopsy specimens from renal-cell carcinoma, uterine
carcinoma, breast ductal carcinoma in situ (DCIS), and
thyroid adenoma of patient 22701 were evaluated for
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Figure 2 PTEN sequences from genomic DNA (gDNA), tumor DNA, and constitutional cDNA, from families with inherited mutations
in this tumor-suppressor gene. Heterozygosity for inherited mutations in genomic DNA is illustrated for probands from seven families. Sequences
may be either sense or antisense; mutations are indicated for the sense strand. Sequence “22701-tumor” reflects hemizygosity for the mutant
PTEN allele in DNA from the renal-cell carcinoma of patient 22701. Sequences “24101 cDNA,” “1163.1 cDNA,” and “9701 cDNA” reflect
the presence of only the wild-type transcript in normal cells from individuals with mutations, consistent with instability of the mutant transcripts.
Sequences of genomic DNA from 9702 and 9703, parents of 9701, are homozygous normal, indicating that the mutation in individual 9701
is de novo.
LOH at PTEN bp 1003 and at markers D10S215,
D10S541, and D10S564. All tumors revealed both LOH
at the three markers and hemizygosity for the mutant
allele at the altered site (fig. 2). Loss of the normal allele
and retention of the mutant sequence support the hy-
pothesis that PTEN acts as a tumor suppressor. Normal
tissue surrounding the renal-cell carcinoma and the uter-
ine carcinoma were heterozygous at bp 1003, as ex-
pected. Interestingly, DNA from apparently normal tis-
sue adjacent to the DCIS and adjacent to the thyroid
adenoma was clearly hemizygous, retaining only wild-
type sequence.
Loss of Mutant Transcripts from Patient mRNA
For families 97, 241, and 1163, cDNA was prepared
from lymphoblast poly(A) RNA, in order to test the
stability of mutant and wild-type transcripts. As shown
in figure 2, mutant transcripts were not detected in RNA
by dye-terminator sequencing. Loss of mutant tran-
scripts from patients with nonsense mutations is consis-
tent with degradation of these transcripts through a non-
sense-mediated pathway (Decker and Parker 1994;
Maquat 1996).
Discussion
The genetics of germ-line mutations in PTEN is con-
sistent with its somatic genetics and biochemistry, all of
which indicate that the gene is a tumor suppressor for
breast and other cancers (Li and Sun 1997; Li et al. 1997;
Liaw et al. 1997; Steck et al. 1997). The PTEN gene has
distinctive features at the levels of cells, families, and
species. First, the gene is highly conserved. Human and
mouse amino acid sequences are 197% identical (Steck
et al. 1997). The gene is also highly conserved within
humans.
Second, consequences of even minimal mutations may
be profound, even at the level of transcription. Non-
sense-mediated mRNA degradation leading to transcript
instability has been characterized in several species
(Leeds et al. 1991; Pulak and Anderson 1993; Cui et al.
1995). Nonsense-mediated mRNA degradation may
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play a role in the reduced mRNA expression of disease-
related nonsense mutations (Dunn et al. 1989; Lim et
al. 1992; Friedman et al. 1994; Menon and Neufeld
1994). The absence of mutant transcripts in cDNA from
affected individuals with PTEN germ-line nonsense mu-
tations suggests that the PTEN mutant transcript may
be degraded by a nonsense-mediated pathway.
Third, a high fraction of tumors have deleted the gene
and some flanking sequence. The phenotypes associated
with either somatic or germ-line mutations are highly
variable. In the same person, one germ-line mutation
and several somatic mutations may lead to tumors in
multiple organ systems. The multiple hamartomas in
various organs suggest expression in early development
and tissue differentiation. A gene critical to early de-
velopment could well be highly conserved among
species.
Lhermitte-Duclos disease is observed in some families
with CD and is associated with severe neurological
symptoms (Lhermitte and Duclos 1920; Albrecht et al.
1992). None of the patients with detected PTEN mu-
tations in our series were diagnosed with Lhermitte-Du-
clos disease. Because mutations in these families were
found throughout the gene, and because mutations in
families with Lhermitte-Duclos disease have been ob-
served in exons 2 and 5–7 and in intron 4 (Liaw et al.
1997; Nelen et al. 1997), it appears unlikely that mu-
tations causing Lhermitte-Duclos disease cluster in any
one region of PTEN.
Fourth, a high proportion of observed mutations are
new, rather than persisting over several generations or
recurring as founder mutations in individuals who are
not closely related. PTEN mutations that were observed
in more than one family are independent events. These
characteristics may reflect mutation and selection inter-
acting in a particularly dramatic way for an important
gene. PTEN may be vulnerable to the entire range of
types of mutations, but the gene may be so functionally
constrained and so ubiquitously expressed that essen-
tially no alterations are benign.
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